Tiny Gem Archives

TuesdayFeb 17, 2026 10:00 am

Existing Cancer Drug Shows Potential in Reactivating Immunotherapy

An already approved cancer drug called Carfilzomib may help restore the effectiveness of CAR-T cell therapy in advanced multiple myeloma cases. Technical University of Munich researchers have discovered a molecular mechanism that causes cancer cells to evade treatment and have shown that blocking it can make immunotherapy work again in some patients. CAR-T cell therapy involves removing a patient's T cells, genetically altering them in the laboratory, and reintroducing them so they can recognize and attack cancer cells. For multiple myeloma, these engineered cells target a molecule known as BCMA, which appears on diseased plasma cells. The approach can extend survival, sometimes by years,…

FridayFeb 13, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a picture of a company advancing on multiple fronts LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its…

WednesdayFeb 11, 2026 10:00 am

New AI Model Predicts Dementia Risk, Cancer Survival and Brain Age

Mass General Brigham researchers have developed a new AI model that can estimate brain age, assess a patient’s risk of developing dementia, and help predict survival outcomes for brain cancer using routine MRI scans. The system, created within the Harvard-affiliated health network, is designed to pull multiple clinical signals from a single brain image rather than being trained for one narrow diagnostic task. Known as BrainIAC, the model takes a different approach from most medical AI tools currently in use. Instead of relying on massive, carefully labeled datasets tied to one disease or outcome, BrainIAC is built to adapt across a range of neurological and oncology-related problems. Researchers say that…

MondayFeb 09, 2026 10:00 am

Investors React Positively to Meta’s Plan to Increase AI Capex

Investors are responding positively to Meta’s decision to keep increasing artificial intelligence spending, even as fears grow that the AI boom could be inflating a bubble. While concerns about a potential bust are becoming more common, Meta’s latest earnings suggest that, for now, the market is still willing to back heavy investment, particularly when it produces clear financial results. Those fears are not unfounded. A growing share of AI spending is circular in nature, and the circular investment nature among companies involved in AI has raised concerns about artificial demand propping up valuations. Large tech companies are buying chips, cloud capacity, and services from the same small group of firms…

MondayFeb 09, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s…

WednesdayFeb 04, 2026 11:15 am

Improving the Odds: How LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective

LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance Clinical programs are designed to enhance existing immunotherapies and chemotherapies rather than replace them Multiple active trials across ovarian clear cell cancer, colon cancer, and soft tissue sarcoma support a platform approach Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can produce meaningful responses, yet durability and consistency remain challenges, particularly in aggressive or rare cancer subtypes. Increasingly, research is shifting toward approaches that improve how well…

WednesdayFeb 04, 2026 10:00 am

Scientists Discover Why Immunotherapy Frequently Fails

Although cancer immunotherapy has transformed treatment for many patients, the promise of effective immunotherapy falls short for many patients. Scientists now believe they have identified a major reason why immunotherapy isn't always effective. New research shows that cancer cells rely on a previously hidden escape route to weaken immune attacks, and a class of widely used medications may help block it. The study, led by Professor Kunihiro Tsuchida at Fujita Health University, suggests that cancer cells do more than evade immune checkpoints. They actively distribute immune-suppressing signals throughout the body, reducing the effectiveness of immunotherapy even when tumors appear responsive based on standard markers. Immunotherapy drugs such as PD-1 and PD-L1 inhibitors work by releasing the…

WednesdayFeb 04, 2026 9:45 am

GridAI Technologies Corp. (NASDAQ: GRDX) Targeting Energy Control Bottleneck Facing AI Data Centers

Power availability and control are emerging as binding constraints on AI data center growth, with efficient energy control now seen as critical to the financial viability of hyperscale AI campuses. GridAI focuses its AI-native software on energy orchestration rather than power generation or hardware, operating at the intersection of utilities, power markets, and large AI-driven electricity demand. The company’s technology manages energy flows outside the data center, across grid assets, storage, and on-site generation. For much of the past decade, the investment narrative around artificial intelligence has revolved around semiconductors, cloud platforms, and talent. More recently, attention has shifted to…

TuesdayFeb 03, 2026 11:15 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Positions for Urban Counter-Drone Demand with Cyprus Deal

ParaZero entered the Cyprus market via a reseller agreement with homeland security specialist Lella Kentonis The firm’s counter-UAS technologies are built for complex, contested, and civilian-dense environments These updates underscore ParaZero’s mission to create and deliver scalable, low-collateral drone mitigation as threats move into the cities from the battlefields ParaZero Technologies (NASDAQ: PRZO) is stepping up efforts targeted at its global expansion strategy as hostile drone threats extend into urban and civilian areas. The company recently announced that a reseller arrangement had been reached with Lella Kentonis Investment Co. Limited, engaging the services of the homeland security specialist as its…

MondayFeb 02, 2026 11:15 am

Rail Vision Ltd. (NASDAQ: RVSN) Subsidiary Achieves Quantum Error Correction Breakthrough

The new decoder leverages transformer-based neural network architecture to generalize across multiple quantum error correction code families and noise profiles. This development is noteworthy because quantum error correction represents one of the most formidable challenges in scaling quantum computing technologies. Rail Vision’s broader narrative has increasingly embraced innovation at the confluence of artificial intelligence, machine learning and transportation safety. Rail Vision (NASDAQ: RVSN) has recently announced that its majority-owned subsidiary, Quantum Transportation Ltd., has developed and validated a first-generation transformer-based neural decoder. The new decoder has demonstrated superior accuracy and efficiency in comprehensive simulations for universal quantum error correction compared…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem